Enalapril

SCHEMBL10390115

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Enalapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

	gene	UniProt	supporting neighbours	confidence
▸	ACE known ✓	P12821	14/20	0.91

▸	SMN1; SMN2	Q16637	1/20	1.00

▸	LMNA	P02545	2/20	0.91

▸	ABCB11	O95342	2/20	0.65

▸	MEN1	O00255	2/20	0.63

▸	KMT2A	Q03164	2/20	0.63

▸	USP2	O75604	1/20	0.63

▸	CYP3A4	P08684	1/20	0.63

▸	ALOX15	P16050	1/20	0.63

▸	PDE3A	Q14432	1/20	0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Enalapril SCHEMBL20817249	1.00	SMN1; SMN2 (1.00)	SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL10	1.00	SMN1; SMN2 (1.00)	SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL2719411	1.00	SMN1; SMN2 (1.00)	SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL9	1.00	SMN1; SMN2 (1.00)	SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL6155137	1.00	SMN1; SMN2 (1.00)	SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL1650291	1.00	SMN1; SMN2 (1.00)	SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL308603	1.00	SMN1; SMN2 (1.00)	SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL825430	1.00	SMN1; SMN2 (1.00)	SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL9019924	0.99	SMN1; SMN2 (0.98)	SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL9019927	0.99	SMN1; SMN2 (0.98)	SMN1; SMN2ACELMNAABCB11MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-4898732-A	Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system	THE CLINIPAD CORPORATION (US)	1990-02-06	—	—	US	disclosed